Scarica l'app Stockscreener
36.01
0.36%
-0.13
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$36.14
Aprire:
$36.32
Volume 24 ore:
2.03M
Relative Volume:
0.54
Capitalizzazione di mercato:
$15.57B
Reddito:
$2.31B
Utile/perdita netta:
$1.66B
Rapporto P/E:
15.66
EPS:
2.3
Flusso di cassa netto:
$827.02M
1 W Prestazione:
-0.17%
1M Prestazione:
-0.47%
6M Prestazione:
+15.38%
1 anno Prestazione:
+30.99%
Intervallo 1D:
$35.95
$36.36
Intervallo di 1 settimana:
$35.35
$36.48
Portata 52W:
$24.05
$38.00
Royalty Pharma Plc Stock (RPRX) Company Profile
Nome
Royalty Pharma Plc
Settore
Industria
Telefono
(212) 883-0200
Indirizzo
110 EAST 59TH STREET, NEW YORK, NY
Confronta RPRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
36.01 | 15.62B | 2.31B | 1.66B | 827.02M | 2.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-30 | Iniziato | Goldman | Buy |
| 2025-05-16 | Iniziato | Morgan Stanley | Overweight |
| 2024-06-03 | Downgrade | UBS | Buy → Neutral |
| 2022-06-14 | Ripresa | UBS | Buy |
| 2022-05-13 | Iniziato | Scotiabank | Sector Outperform |
| 2022-04-27 | Iniziato | Goldman | Buy |
| 2022-04-14 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2021-10-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-07-30 | Iniziato | Tigress Financial | Buy |
| 2020-11-09 | Aggiornamento | UBS | Neutral → Buy |
| 2020-07-14 | Iniziato | Evercore ISI | In-line |
| 2020-07-13 | Iniziato | BofA Securities | Buy |
| 2020-07-13 | Iniziato | Citigroup | Neutral |
| 2020-07-13 | Iniziato | Cowen | Outperform |
| 2020-07-13 | Iniziato | Goldman | Neutral |
| 2020-07-13 | Iniziato | JP Morgan | Neutral |
| 2020-07-13 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Iniziato | SunTrust | Buy |
| 2020-07-13 | Iniziato | UBS | Neutral |
Mostra tutto
Royalty Pharma Plc Borsa (RPRX) Ultime notizie
Why Royalty Pharma plc (RPD) stock could rally stronglyJuly 2025 Sector Moves & Risk Controlled Stock Alerts - newser.com
Is this a good reentry point in Royalty Pharma plc2025 Volatility Report & Expert Curated Trade Setups - newser.com
Royalty Pharma To Announce Third Quarter 2025 Financial Results On November 5, 2025 - TradingView
Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025 - The Manila Times
Q3 2025 Results Nov 5: Royalty Pharma to Report Results and Host Call/Webcast at 8:00 a.m. ET - Stock Titan
Custom watchlist performance reports with Royalty Pharma plcPortfolio Profit Report & Safe Capital Growth Tips - newser.com
Royalty Pharma (NASDAQ:RPRX) Raised to Buy (B-) at Weiss Ratings - MarketBeat
Is Royalty Pharma plc stock a smart buy before Fed meeting2025 Top Gainers & AI Enhanced Execution Alerts - newser.com
Will Royalty Pharma (RPRX) Beat Estimates Again in Its Next Earnings Report? - sharewise.com
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises - Yahoo Finance
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - sharewise.com
Why Royalty Pharma plc stock is a must watch in 2025Weekly Trading Summary & AI Optimized Trade Strategies - newser.com
Understanding Royalty Pharma plc’s price movementMarket Growth Review & Accurate Technical Buy Alerts - newser.com
A Look at Royalty Pharma’s (RPRX) Valuation Following Imdelltra Royalty Acquisition and Board Enhancement - Sahm
Will Royalty Pharma plc stock see PE expansion2025 Analyst Calls & AI Driven Price Predictions - newser.com
What candlestick patterns are forming on Royalty Pharma plcStop Loss & Growth Focused Investment Plans - newser.com
Royalty Pharma collaborates with Biogen for R&D funding - MSN
Royalty Pharma PLC $RPRX Position Increased by Robeco Institutional Asset Management B.V. - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Given Average Rating of "Buy" by Analysts - MarketBeat
11% Of This Royalty Pharma Insider's Holdings Were Sold - 富途牛牛
Will Royalty Pharma's (RPRX) Governance Shift Sharpen Its Edge in Life Sciences Investment? - simplywall.st
The Goldman Sachs Group Initiates Coverage on Royalty Pharma (NASDAQ:RPRX) - MarketBeat
The Best Biotech Stocks to Buy - Morningstar
Goldman Sachs initiates Royalty Pharma stock with Buy rating, $42 target - Investing.com Nigeria
Royalty Pharma : Q3 2025 Pre-Quarterly Results Communication - MarketScreener
Goldman Sachs Initiates Coverage of Royalty Pharma (RPRX) with Buy Recommendation - Nasdaq
Royalty Pharma plc Stock Analysis and ForecastPrice Action Analysis & High Profit Investment Ideas - earlytimes.in
Goldman Sachs Starts Royalty Pharma (RPRX) at Buy, PT $42 - StreetInsider
Royalty Pharma appoints Ted Love as lead independent director By Investing.com - Investing.com Nigeria
We Think Royalty Pharma (NASDAQ:RPRX) Can Stay On Top Of Its Debt - 富途牛牛
Royalty Pharma : Bernstein Healthcare Forum Transcript - MarketScreener
Royalty Pharma appoints Ted Love as lead independent director - Investing.com
Royalty Pharma names Dr. Ted Love as lead independent director - StreetInsider
Biotech Leader Ted Love Takes Key Board Role at Royalty Pharma, Bringing BIO Leadership Experience - Stock Titan
Overbrook Management Corp Trims Position in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director - The Globe and Mail
Royalty Pharma Plc Azioni (RPRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):